MARKET

CGEM

CGEM

Cullinan Oncology Inc
NASDAQ
11.23
-0.50
-4.26%
Closed 19:55 11/10 EST
OPEN
11.71
PREV CLOSE
11.73
HIGH
12.04
LOW
10.95
VOLUME
810.43K
TURNOVER
0
52 WEEK HIGH
23.19
52 WEEK LOW
7.25
MARKET CAP
722.70M
P/E (TTM)
-3.3844
1D
5D
1M
3M
1Y
5Y
1D
Cullinan Therapeutics Braces for Costly SEC Shift as It Loses Smaller Reporting Company Status by 2026
TipRanks · 4h ago
Cullinan Buy Rating Reaffirmed at $36 as CLN-978 and CLN-049 Clinical Catalysts Approach
TipRanks · 12h ago
Cullinan Therapeutics reports Q3 EPS (74c), consensus (84c)
TipRanks · 17h ago
Cullinan Therapeutics reports Q3 results
Seeking Alpha · 19h ago
Cullinan Therapeutics Q3 EPS $(0.74) Beats $(0.84) Estimate
Benzinga · 22h ago
Press Release: Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Dow Jones · 22h ago
Press Release: Cullinan Therapeutics Provides -2-
Dow Jones · 22h ago
Cullinan Therapeutics: Q3 Earnings Snapshot
Barchart · 1d ago
More
About CGEM
Cullinan Therapeutics, Inc. is a biopharmaceutical company. It has built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in autoimmune diseases and cancer. Its portfolio includes a range of modalities. Its pipeline includes CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. CLN-978 is a CD19xCD3 T cell engager being developed for autoimmune diseases. CLN-619 is a monoclonal antibody that stabilizes expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by cytotoxic innate and adaptive immune cells. Zipalertinib (CLN-081/TAS6417) is an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor. CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-617 is a fusion protein combining two potent antitumor cytokines, interleukin-2 and interleukin-12 with tumor retention domains for the treatment of solid tumors.

Webull offers Cullinan Therapeutics Inc stock information, including NASDAQ: CGEM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CGEM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CGEM stock methods without spending real money on the virtual paper trading platform.